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MicroRNAs (miRNAs) represent a class of small non-coding RNA (sncRNA) molecules 
that can regulate mRNAs by inducing their degradation or by blocking translation. 
Considering that miRNAs are ubiquitous, stable, and conserved across animal species, 
it seems feasible to exploit them for clinical applications. Unlike in human viral diseases, 
where some miRNA-based molecules have progressed to clinical application, in veter-
inary medicine, this concept is just starting to come into view. Clinically, miRNAs could 
represent powerful diagnostic tools to pinpoint animal viral diseases and/or prognostic 
tools to follow up disease progression or remission. Additionally, the possible conse-
quences of miRNA dysregulation make them potential therapeutic targets and open the 
possibilities to use them as tools to generate viral disease-resistant livestock. This review 
presents an update of preclinical studies on using sncRNAs to combat viral diseases 
that affect pet and farm animals. Moreover, we discuss the possibilities and challenges 
of bringing these bench-based discoveries to the veterinary clinic.
Keywords: animals, animal viruses, biomarkers, clinical application, infectious diseases, miRNA, small non-
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iNTRODUCTiON
Small non-coding RNAs (sncRNAs) are classes of short RNAs, which do not encode proteins, 
but rather perform regulatory functions by engaging target transcripts through sequence-specific 
interactions. Among these, microRNAs (miRNAs) are single-stranded molecules roughly 22 nt in 
length (1). The regulatory network and function of miRNAs are based on the fact that more than one 
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swine fever virus; DMVD, degenerative mitral valve disease; FDA, Food and Drug Administration; FFPE, formalin-fixed, 
paraffin-embedded tissue; FMD, foot-and-mouth disease; FMDV, foot-and-mouth disease virus; GFP, green fluorescent 
protein; HA, hemagglutinin; HDLP, high-density lipoprotein; IAV, influenza A virus; LNA, locked nucleic acids; miRNA, 
microRNAs; PA, polymerase acidic; PB-1, polymerase basic 1; PPMOs, NP, nucleoprotein peptide-conjugated morpholino 
oligomers; PrPc, prion protein of cell; RISC, RNA-induced silencing complex; RNAi, RNA interference; ROC, receiver operating 
characteristic; RV, rabies virus; SA, sialic acid; shRNA, short hairpin RNA; siRNA, small interfering RNA; sncRNAs, small 
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miRNA species can target the same mRNA (cooperativity) and 
that one miRNA can target hundreds of mRNA species (multi-
plicity) (2). The binding of miRNAs to the 3′ untranslated region 
(UTR) of particular mRNA leads to either mRNA degradation 
or protein translation repression (3). miRNAs can be highly 
regulated both in pattern and degree of expression across mul-
tiple animal diseases. Targeting hundreds of host and pathogen 
encoded genes, a single miRNA can influence the gene networks 
essential for development and progression of a disease condition 
(4). This, coupled with their high degree of conservation, has 
made miRNAs attractive candidates for clinical application to 
combat pathogenic animal viruses. Being highly stable, they can 
be used as disease biomarkers (5). The availability of chemically 
synthesized miRNA mimics and agonists and vector-based RNA 
interference (RNAi) technology raised the idea of therapies based 
on non-coding RNA and made it feasible to utilize this approach 
to create genetically modified animal breeds that are resistant to 
certain viral pathogens. In this review, we summarize the current 
state of laboratory studies geared toward clinical applications of 
sncRNAs [miRNAs, small interfering RNAs (siRNAs), and short 
hairpin RNAs (shRNAs)] to diagnose and combat viral diseases 
that affect animals of veterinary importance and may thus impact 
animal and human health.
miRNAs AS CANDiDATeS FOR CLiNiCAL 
APPLiCATiON TO COMBAT ANiMAL 
viRAL DiSeASeS
Potential Biomarkers
The emerging correlation between miRNA expression and 
disease pathogenesis and outcomes suggests the potential use of 
miRNAs as biomarkers. In the first report that described the role 
of a miRNA as a diagnostic and prognostic marker in humans, 
Takamizawa et al. demonstrated that in patients with lung cancer, 
lower let-7 levels predicted a significantly worse prognosis after 
potentially curative resection (6). The intense use of advanced 
genomic technologies has resulted in rapid progress in human 
personalized medicine, where biomarker studies play a central 
role. Similar research interest has been emerging in veterinary 
medicine, albeit with some delay. Indeed, Henry et al. reported in 
2010 that biomarker studies in veterinary medicine were still lag-
ging behind those in humans (7). Biomarker research in the field 
of veterinary medicine focuses on the health and welfare of farm 
and companion animals as well as broader aspects, such as the 
biosafety of animal-derived food and milk production. Generally, 
the potential applications for biomarkers in veterinary clinics 
include diagnosis, staging, prognosis, and monitoring responses 
to therapy. Although several well-established biomarkers have 
been recognized for a number of veterinary viral diseases, there 
are still many barriers. As one example of many, lack of specificity 
has been recorded when using acute phase proteins (APPs) as 
biomarkers in pig, horse, and cattle suffering from inflammatory 
conditions that may have infectious etiologies, such as foot-and-
mouth disease virus (FMDV) infection, porcine reproductive and 
respiratory syndrome virus infection, pneumonia, arthritis, enter-
itis, and post-castration inflammation (8–10). The concentration 
of some available biomarker molecules is affected by animal age 
(11). Thus, there is a need for additional, improved biomarkers for 
animal diseases. There is growing recognition that miRNAs may 
provide a specific signature that reflects the existence of a given 
clinical state. In this regard, the results of profiling the fluctuation 
of miRNA expression levels in infected organs, tissues, or single 
cells compared to uninfected ones throughout the course of a 
disease might reflect severity and outcome of the disease, includ-
ing the likelihood of response to a given therapy. As biomarkers, 
miRNAs represent ideal candidates owing to their biological and 
clinical relevance, practicality, and consistent correlation with 
disease activity. The biological rational behind using miRNAs as 
biomarkers arises from their involvement in diverse physiologi-
cal and pathological processes. miRNAs are extremely practical, 
with many advantages over other currently used biomarkers. 
For instance, there are efforts to develop them into diagnostics 
for the differentiation between viral and bacterial infections, 
each of which typically requires different interventions, such as 
quarantining versus feeding of antibiotics. The smaller number of 
identified miRNAs (12), compared to the approximately 30,000 
protein-encoding genes currently known, implies that computa-
tional approaches dealing with miRNAs would be simpler and 
would require fewer resources than proteomics- or mRNA-based 
approaches. Another merit of miRNAs is their resistance to 
degradation by ribonucleases. For instance, they are stable in 
formalin-fixed, paraffin-embedded tissue (FFPE) independent of 
formalin fixation time and duration of tissue block storage (13). 
In contrast, mRNAs are highly fragmented and unstable in FFPE, 
which is problematic when FFPE is the only available sample type 
or when long storage of FFPE blocks has led to mRNA degrada-
tion (13). miRNAs can be detected in a large number of easily 
accessible samples, such as tissue biopsies, whole blood, blood 
cells, cerebrospinal fluid, saliva, urine, and other body fluids. 
Circulating miRNAs have proven to be highly resistant against 
RNAse activity, extreme pH, and temperature, and certainly 
more so than mRNAs. This is, at least in part, because they are 
often contained in lipid vesicles (microvesicles and exosomes) or 
bound by RNA-binding proteins (5). Additionally, miRNAs resist 
prolonged exposure to room temperature and repeated freezing/
thawing cycles. Some miRNAs may be uniquely expressed only in 
specific body fluids, as exemplified by miR-224 (plasma/serum), 
miR-637 (tears), miR-193b (breast milk), and miR-508-5p 
(seminal fluid) (14). As opposed to miRNAs, proteins are a much 
more complex family of molecules due to use of alternate reading 
frames, splice variants, and various post-translational modifica-
tions, and many proteins of interest are of low abundance and/or 
may display major sequence variations among clinically relevant 
species (5).
MicroRNAs as Shared Biomarkers in Human and 
Animal Disease
In order to assess the role of miRNAs as a class of shared biomark-
ers, it is important to investigate the cross-species conservation 
and regulation of the same miRNA species or miRNA family. 
Most of the annotated miRNAs are evolutionarily conserved 
among a variety of organisms, particularly in their mature form, 
FiGURe 1 | Sequence alignment of the mature form of miR-146b-5p among animals and humans. The open box illustrates the high degree of conservation 
of the seed region of miR-146b-5p. Accession numbers are according to miRBase 21 (12).
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suggesting that the majority of miRNAs constitute a large class 
of predominantly orthologous or homologous molecules. As 
exemplified by miR-146b-5p, cross-species variation in miRNA 
sequence is typically observed in 1 or 2  nt in the periphery of 
the mature form and in its 3′ UTR, i.e., away from the highly 
conserved seed region (Figure  1). This unique conservation 
pattern might be attributed to the conservation of their genomic 
origin. It has been reported that a consensus motif of 7–8  nt 
upstream and downstream of the pre-miRNA hairpin was found 
to be conserved among nematodes (15). Researchers from 
Slovenia and the USA have put together a catalog to describe the 
integrated assembly of intragenic miRNAs and their host genes 
in humans, mouse, and chicken (16). They showed that several 
miRNA genes were located within homologous areas, which 
implies that miRNA colocalization, co-expression, and potential 
coregulation may be conserved broadly across evolution and thus 
be applicable to both animal and human diseases. In the same 
context, previous studies reported that 300 canine miRNAs are 
homologs of annotated human miRNAs and that miRNA clusters 
are usually conserved between humans and dogs (17). Using 
next generation sequencing, Li et al. indicated that miRNAs in 
immune organs of chicken and duck were about 99% conserved 
(18). To gain further insights into miRNAs that are shared 
between species and might be used as common biomarkers, we 
selected a group of miRNAs that are commonly expressed upon 
influenza A virus (IAV) infection in humans and chicken. These 
miRNAs were further analyzed with miRviewer (19), a database 
that includes all known miRNAs of currently annotated animal 
genomes. William Pearson’s aligning program was used to assess 
the degree of conservation of mature miRNAs between the two 
species (Table 1). The percentage of sequence identity was further 
confirmed by the Bioedit sequence alignment editor (20). Indeed, 
there is a high degree of conservation of most miRNAs between 
the two species (Table 1). For some miRNAs, there are sequence 
differences between humans and chicken in the form of deletion 
or addition of extra nucleotides, but these are mostly located out-
side the seed region. We speculate that conserved miRNAs might 
be the most promising candidates for universal biomarkers that 
may help in simultaneously pinpointing a given disease state in 
both species. In contrast, the non-conserved miRNAs might have 
the least contributory role as universal biomarkers but may play 
roles in more species-specific aspects of disease pathogenesis and 
outcomes. Apart from the sequence conservation of miRNAs, 
the presence of the same miRNA signatures in both humans and 
animals upon contracting the same infectious disease  supports 
the concept of common biomarkers. Taken together, these 
observations indicate that cross-species comparisons of human 
and animal miRNA expression profiles as well as their conserva-
tion could provide unique opportunities to exploit miRNAs as 
universal biomarkers and also underline both commonalities and 
differences in  pathology of the same disease in different species.
Limitations in Using miRNAs as Biomarkers to 
Combat Viral Diseases
While using miRNAs as novel biomarkers in the veterinary field 
represents a promising concept, it comes with unique challenges. 
One challenge is the presence of miRNA isomers (isomiRs), i.e., 
forms of miRNA that differ slightly from the annotated mature 
sequence. They are likely created by the enzymatic addition 
of adenine, cytidine, or uridine and/or imprecise cleavage by 
the enzymes Dicer or Drosha (21). Observational studies have 
shown that isomiRs can be regulated upon infection and hence 
are biologically and functionally meaningful (22). There is some 
functional overlap between miRNAs and their isomers (23). 
However, most miRNA annotation tools ignore these isomers 
by considering them as either noise or sequencing artifacts. The 
presence of isomiRs might affect miRNA stability and repression 
capability (24) and therefore reduce their value as biomarkers. 
TABLe 1 | Sequence conservation of selected mature miRNAs in humans and chicken.a
miRNA identity (%) Human and chicken miRNA sequences Accession number
mir-29a 95.2 Human UAGCACCAUCUGAAAUCGGUUA MIMAT0000086
Chicken UAGCACCAUUUGAAAUCGGUU- MIMAT0001096
mir-18a-5p 100.0 Human UAAGGUGCAUCUAGUGCAGAUAG MIMAT0000072
Chicken UAAGGUGCAUCUAGUGCAGAUA- MIMAT0001113
mir-32-5p 100.0 Human UAUUGCACAUUACUAAGUUGCA MIMAT0000090
Chicken UAUUGCACAUUACUAAGUUGC- MIMAT0001125
mir-223-3p 100.0 Human UGUCAGUUUGUCAAAUACCCCA MIMAT0000280
Chicken UGUCAGUUUGUCAAAUACCCC- MIMAT0001140
mir-34a-5p 100.0 Human UGGCAGUGUCUUAGCUGGUUGU- MIMAT0000255
Chicken UGGCAGUGUCUUAGCUGGUUGUU MIMAT0001173
mir-142-3p 100.0 Human UGUAGUGUUUCCUACUUUAUGGA MIMAT0000434
Chicken UGUAGUGUUUCCUACUUUAUGG- MIMAT0001194
miR-155-5p 100.0 Human UUAAUGCUAAUCGUGAUAGGGGU MIMAT0000646
Chicken UUAAUGCUAAUCGUGAUAGGGG- MIMAT0001106
amiRNAs are listed in ascending numerical order. Non-conserved nucleotides are printed in red. Accession numbers of miRNAs sequence are according to MiRBase 21.
April 2016 | Volume 3 | Article 224
Samir and Pessler sncRNAs in Veterinary Infectious Diseases
Frontiers in Veterinary Science | www.frontiersin.org
When looking for miRNAs as circulating biomarkers, it is 
important to consider the low miRNA yield (1–10 ng/μl) in body 
fluids, such as plasma, serum, and urine (25). While some studies 
suggested that plasma contains a higher miRNA concentration 
than serum (26), a growing body of evidence has indicated that 
using serum as a biological sample for miRNA biomarker studies 
might be biased (27). This is because the stress that blood cells 
are exposed to during coagulation results in the release of nucleic 
acids, including miRNAs into the serum, which may change the 
true repertoire of circulating serum miRNAs giving rise to biased 
values. With this in mind, the lack of correlation in detection of 
some miRNAs in plasma and serum is not unexpected. Prior cen-
trifugation of the blood and hemolysis might affect the amount 
and stability of the target miRNA and require some modifications 
in the isolation protocols (26). Moreover, difficulties in miRNA 
extraction can compromise yield and quality (28). Considering 
that miRNAs are differentially expressed among different animal 
breeds (29, 30), it is plausible that miRNA levels may differ among 
different animal breeds if they contract the same disease. This 
is also apparent among humans where the expression of some 
miRNAs was found to be related to ethnicity. In this regard, 
receiver operating characteristic (ROC) curve analysis indicated 
that let-7c predicted the onset of breast cancer with an area under 
the curve (AUC) of 0.99 in African Americans while having an 
AUC of only 0.78 in Caucasians. On the other hand, the best pre-
dictor in Caucasians was miR-589 with an AUC of 0.85 (31). This 
holds true for other biomarkers as well. Two reports documented 
a significant breed effect on the level of plasma NT-proBNP, a 
diagnostic marker in dogs with degenerative mitral valve disease 
(DMVD) (32, 33).
RNA interference as a Promising Tool for 
Therapeutic intervention
RNA interference is a form of post-transcriptional gene silenc-
ing that can function in a broad range of eukaryotic species. 
Fighting animal viruses with RNAi can be mediated by using 
siRNA or miRNAs, although the origin of both molecules is 
different. While miRNAs are endogenously produced through-
out two processing steps in nucleus and cytoplasm, siRNA can 
be exogenously introduced directly into the cytoplasm as a 
double strand (34). Once in the cytoplasm, both miRNA and 
siRNA pass through the same processing steps where they are 
digested by the Dicer enzyme to form a duplex. Only one strand 
of this duplex is translocated into the RNA-induced silencing 
complex (RISC) to mediate its function (35). While siRNA 
forms a perfect complementarity with its target mRNA, caus-
ing its cleavage, miRNAs tend to bind to their mRNA targets 
less perfectly leading to repression in translation. Historically, 
laboratory-based experiments of using RNAi to block the repli-
cation of animal viruses started early on, namely in 2003 against 
IAV (36). Harnessing miRNAs for therapeutic use will rely on 
using gain and loss of function and is linked to the expression 
level of the miRNA (35). miRNAs that are beneficial for the 
virus and are up-regulated upon infection might be blocked 
using classic or modified anti-miRNAs (37). In this regard, 
antagomiRs (cholesterol conjugated anti-miRNAs) have been 
used in vitro and in vivo (38). Chemically modified nucleotides, 
such as locked nucleic acid (LNA), and other modifications 
have made it conceivable to design more stable and specific 
oligonucleotides. In an in  vivo system, reports stated that the 
effect of using LNA proved to be long-lasting and safe, as neither 
toxicity associated with LNA nor histopathological changes were 
detected (39). Although there are attempts to downregulate the 
Dicer or Drosha enzymes as indirect ways to block miRNAs, this 
mechanism should be strictly controlled since blocking these 
enzymes will affect the entire miRNA population (40). In cases 
where miRNAs tend to inhibit virus replication, a therapeutic 
approach could be to over-express these miRNAs or to restore 
their levels. In this context, synthetic miRNA mimics resembling 
mature miRNAs that could be recognized by RISC would be a 
suitable tool (40). The in vivo delivery of miRNA modalities to 
specific cells has remained a substantial barrier. Using viruses or 
virus-like vectors might be innovative approaches since viruses 
have evolved over many generations to infect certain cells and 
to deliver foreign RNA, including miRNA, in a tissue- and 
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cell-specific manner (41). Viral vectors can express pri-miRNA 
or pre-miRNA-like structures or even mature miRNA. Here, 
RNA viruses of both nuclear and cytoplasmic origin have been 
utilized (42). miRNAs may have advantages over siRNAs as 
therapeutic candidates. In spite of having off-target effects, miR-
NAs bind to their targets with partial complementarity (43) and, 
thus, likely tackle the high rate of mutation seen in many viruses 
better than siRNAs. Also, siRNAs can trigger interferon produc-
tion as part of a cellular stress response pathway that can cause 
translation arrest, growth inhibition, and cytotoxicity (44). In 
contrast to the shRNA approach, the use of miRNAs enables the 
expression of multiple miRNAs from a single transcript as com-
pared to only one in regular shRNA vectors. Indeed, transfection 
of cells with two different shRNAs may lead to competition of 
the two for transport and incorporation into the RISC, resulting 
in a reduction in shRNA processing and activity (45). Despite 
reports on efficient silencing of genes using RNAi, differences 
in the efficacy of a given vector between experiments have been 
reported. This might be due to inefficient cellular uptake of the 
RNAi and may also depend on the cell type. What follows is 
an overview and update of the in vitro and in vivo experiments 
aiming at evaluating the potential use of small RNAs, including 
miRNAs, as a treatment option against viral diseases that affect 
animals of agricultural and/or economic importance.
Influenza A Virus
Infection with IAV is a worldwide problem that affects both 
human and animal health (46, 47). The presence of multiple 
viral genotypes and the possibilities of antigenic shift and drift 
continue to raise concerns about the pandemic potential (48, 
49). Current influenza vaccines and therapies have proved to be 
inefficient to combat the continuously evolved IAV strains due 
to the occurrence of antigenic variation within influenza virus 
genomes due to point mutations (drift) or re-assortment (shift) 
(50, 51). The emergence of resistant virus strains added another 
limitation to anti-IAV therapies (52). RNAi formulated in an 
appropriate agent would offer the potential for a new therapy 
by targeting viral transcripts. Furthermore, inserting a let-7b 
response element within the H1N1 genome created an attenu-
ated strain that conferred protection in mice against challenge 
with a lethal strain, suggesting that the attenuated strain might 
serve as a live-attenuated vaccine (53). Around 13,500 possible 
siRNA target sites are present in the IAV genome. Recent reports 
described the usefulness of methods and procedures to select 
highly effective influenza-specific siRNAs in cell culture, mice, 
and ferrets (54). Using in silico approaches, Raza and colleagues 
identified five conserved amino acid sequences, three in the 
hemagglutinin (HA) gene (RGLFGAIAGFIE, YNAELLV, and 
AIAGFIE) and two in the neuraminidase (N) (RTQSEC and 
EECSYP) gene, which might provide potential RNAi-based 
therapeutic targets in various IAV strains (55). RNAi has been 
shown to be effective in suppressing IAV replication both in vitro 
and in vivo. For instance, transfecting MDCK cells with siRNA 
specific for nucleoprotein (NP, nucleotide positions 1496–1514) 
or polymerase acidic (PA, nucleotide positions 2087–2106) 
mRNA sequences inhibited IAV replication (36). Moreover, a 
mixture of siRNAs specific for highly conserved regions of NP 
and PA can protect mice from lethal challenge with IAV of the 
H5 and H7 subtypes [e.g., Ref. (56)]. siRNA against the matrix 
2 (M2) gene exhibited similar or slightly higher reduction in 
virus replication in MDCK cells and in human HEK293 cells 
(57). Likewise, IAV titers in MDCK cells and in embryonated 
eggs were reduced more than 50- and 100-fold, respectively, 
when shRNA targeting the polymerase basic 1 (PB1) gene was 
transfected in vitro and in vivo using a liposome-encapsulated 
pSIREN/PB1 vector. In mice, the survival rate ranged between 50 
and 100% (58). In another experiment, siRNA targeting a region 
of the M1 gene between nucleotides 331 and 351 was found to 
be the most effective in inhibiting M1 protein translation in cell 
lines. Inhibiting the viral M1 protein using this siRNA caused 
an 80% reduction in viral titers in supernatants of siRNA-
transduced MDCK cells at 6, 8, and 10 hpi. Furthermore, virus 
budding ability was reduced by 40%, suggesting the ability of 
siRNA targeting the M1 protein to suppress IAV replication (59). 
Another report demonstrated the efficacy of anti-NP and anti-
PA shRNAs in reducing IAV titers in MDCK cells and in avian 
CH-SAH cells. Significant decreases of up to 80% in the levels of 
IAV NP mRNA and up to 370-fold in viral titer were observed 
in the CH-SAH cells. The approach also worked well in MDCK 
cells, as demonstrated by significant decreases up to 90% in the 
level of viral mRNA, and up to 106-fold in IAV infective titer. 
Furthermore, the authors identified a novel, highly efficient, and 
conserved RNAi target site in the viral NP gene, which can be 
used in antiviral cocktails of shRNAs to prevent IAV escape from 
RNAi silencing (60). Zhou and colleagues investigated the silenc-
ing effect of M2 and NP-specific siRNAs on IAV (H5N1, H1N1, 
and H9N2) replication in cell lines and mice (61). In the cell lines, 
a 0.51–1.63 TCID50 reduction in virus titers was observed, and 
delivery of pS-M48 and pS-NP1383 significantly reduced lung 
virus titers in the infected mice (16- to 50-fold reduction in titer) 
and partially protected them from lethal IAV challenge. As an 
alternative approach, targeting host cell genes that are crucial for 
IAV replication can be conducted to control the virus. Expression 
of α2,3-linked (avian-type) and α2,6-linked (human-type) sialic 
acid (SA) receptors on host tissues is considered one of the host 
range and tissue tropism determinants of influenza viruses. An 
siRNA duplex was used to inhibit IAV binding and internaliza-
tion via silencing ST6GAL1 gene that encodes the β-galactoside 
α-2,6-sialyltransferase I (ST6Gal I), a protein important in SA 
receptor formation (62). In addition, targeting cellular proteases 
has been discussed as a method to suppress IAV replication. 
Rogers and colleagues studied pulmonary miRNA expression in 
mice infected with the IAV H5N1 strain and verified that furin, 
a member of the convertase family that mediates cleavage of 
hemagglutinin, is a target gene for miRNAs upon H5N1 infec-
tion (63). This highlights the importance of using miRNAs as 
potential therapeutic agents against IAV.
Venezuelan Equine Encephalitis Virus
Venezuelan equine encephalitis virus (VEEV) belongs to the 
genus alphavirus in the family Togaviridae. This virus is still 
endemic in many parts of the world and is considered an 
emerging disease threat in other parts as well as a potential 
biological weapon (64). So far, there are no US Food and Drug 
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Administration (FDA) approved drugs or vaccines against VEEV. 
Thus, developing artificial miRNAs that can be used to control 
VEEV infection is a step in the right direction. Indeed, VEEV 
has been targeted efficiently by siRNA (65). Most recently, it was 
shown that targeting the viral non-structural protein-4 (nsp-4) 
region with miRNAs in BHK-21 cells efficiently inhibited viral 
replication, with artificial miR-3 having the greatest effect (66). 
This study indicated that these artificial miRNAs merit further 
testing in animal models for antiviral therapies against VEEV 
infection.
Foot-and-Mouth Disease Virus
Foot-and-mouth disease (FMD) is a highly infectious viral 
disease that usually affects cloven-hoofed animals. The direct 
impact of an FMD outbreak includes great losses to agricul-
tural production and disruption of local economies, while 
the indirect effects lie in the disease control measures at both 
local and global levels and the high cost of disease control and 
prevention programs. FMDV has an RNA genome and many 
serotypes, and targeting conserved viral genes, such as 3D, VP4, 
and 2B, is a major aim in order to control FMD (67). The use 
of peptide-conjugated morpholino oligomers (PPMOs) and 
miRNAs with sequences complementary to various segments 
of the FMDV genome effectively blocked viral replication in 
cell culture models (68). Likewise, DNA vector-based RNAi 
technology can specifically suppress the expression of the VP1, 
3D, VP4, and 2B genes and thus inhibit viral replication in vivo 
and in vitro (67, 69). Using adenovirus-based vectors to express 
siRNA molecules in cell lines and mice, Kim et al. suggested to 
apply RNAi treatments before and after infection with FMDV 
(70). Treatment after FMDV infection inhibited viral replica-
tion effectively, but a combination of treatment before and after 
infection gave the best results in pig kidney cells, IBRS-2 cells, 
and in suckling mice, as evidenced by lower viral titers in cell 
lines and higher survival rates of the treated mice. These experi-
ments did reveal that the RNAi method took considerable time 
to induce a silencing effect, which ranged from 24 to 48 h (71, 
72). This is considered a limitation when attempting to control 
certain rapidly spreading contagious diseases, including FMD, 
as viral spread will be faster than the inhibitory action of the 
RNAi. Finally, the use of artificial miRNAs (amiRs) resulted 
in specific silencing of reporter genes fused to FMDV target 
sequences (73).
Classical Swine Fever Virus
Classical swine fever virus (CSFV) can cause a hemorrhagic 
disease in pigs characterized by disseminated intravascular 
coagulation, thrombocytopenia, and immunosuppression (74, 
75). CSFV has been recognized for nearly 200  years and now 
appears to have been eradicated in Europe and North America 
due to vaccinations and other control measures. The first study of 
using siRNA in blocking CSFV replication was conducted in 2008 
(76). Three siRNA molecules targeting different regions of the 
CSFV Npro and NS5B genes were prepared and transfected into 
PK-15 cells. They caused a 4- to 12-fold reduction in viral genome 
copy number. In another study, synthetic siRNA transfected into 
swine kidney cells (SK-6) could target nucleotides 1130–1148 in 
the nucleocapsid protein (C) of the CSFV with subsequent reduc-
tion in viral titer compared to either mock-treated or non-treated 
cells (77). This emphasizes the potential of siRNA to inhibit CSFV 
replication. Clearly, in vivo experiments need to be conducted to 
confirm this effect.
Rabies Virus
Rabies is a zoonotic disease caused by rabies virus (RV), a 
member of the Rhabidoviridae family. The disease typically 
infects canines (78) and is usually transmitted by animal 
bites, causing a lethal encephalitis. The annual number of 
deaths due to rabies has been estimated to be approximately 
59,000 (79). The control of RV in wild carnivores has moved 
from culling operations to parenteral and oral vaccination of 
susceptible species (80), but inhibiting viral replication with 
siRNA or miRNAs may be another promising approach. Cell 
lines have been used to assess the usefulness of siRNA in 
inhibiting RV replication either by using a pool of siRNAs 
(81) or by single and multiple artificial miRNA targeting RV 
nucleocapsid (N) (45). In these in  vitro assays, there was a 
comparable virus reduction at 72 h post-infection, especially 
when a single miRNA completely matched the target. Similar 
results were reported by others [e.g., Ref. (82)]. In cultured 
cells and murine model, RV glycoproteins were proved to be 
essential for trans-synaptic viral spread between neurons (83). 
This observation encouraged other researchers to target the 
genes encoding such glycoproteins. Sonwane et al. studied the 
ability of adenovirus-based siRNAs, delivered to BHK-21 cells, 
to inhibit RV replication and subsequently tested this approach 
in mice (84). In this study, siRNA inhibited viral replication 
in cell lines and mice. In BHK-21 cells, siRNA targeting the 
RV polymerase gene (L gene) was found to be more effective 
than siRNA targeting the RV NP (N gene) in inhibiting and 
reducing RV replication. Specifically, a 48.2% reduction of RV 
foci was seen in cells, in which the L gene was targeted versus 
a 41.8% reduction when the N gene was targeted. A significant, 
even greater, difference was observed at the mRNA level (17.8- 
versus 5.7-fold reduction). In mice, inoculation of both siRNA 
vectors resulted in a 50% protection against a subsequent lethal 
RV injection. siRNAs simultaneously targeting the glycopro-
tein G and N genes led to an 87% reduction in viral release, 
demonstrating that siRNAs directed against different targets 
may act synergistically and increase efficacy of siRNA-based 
interventions against RV (85). Taken together, the above results 
do suggest that use of siRNAs constitutes a promising approach 
to interventions against RV.
Viral Diseases of Fish
Viral infection in fish aquaculture can be devastating and 
costly (86). Early reports of RNAi-based treatments described 
use of this technology in fish and shellfish in 2008 (87). In fish 
betanodavirus, there are two amino acid residues in the B2 
protein (R53 and R60), which bind viral RNA to circumvent 
the RNAi pathway, underscoring the importance of the antiviral 
role of the host RNAi machinery (88). Dang et al. showed an 
inhibitory effect of siRNA on seabream iridovirus, a marine fish 
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virus (89). In this study, siRNA introduced into cells infected 
with red seabream iridovirus specifically and effectively bound 
to mRNA encoding the virus major capsid protein, leading to a 
reduction in the production of virus particles in the supernatant 
of virus-infected cells, as compared to the cells receiving the 
control treatment. These results provide encouraging evidence 
that siRNA technology might be used to control fish viral dis-
eases. More recently, a shRNA construct was found to inhibit the 
proliferation of viral hemorrhagic septicemia virus by targeting 
its G gene in a sequence-specific manner (90). Infection with 
herpesvirus 3 causes severe financial losses in the common carp 
and koi culture industries worldwide (91). Although most inves-
tigations have employed in vitro approaches, RNAi might be a 
promising tool to combat herpesvirus 3 in carp. For instance, a 
pool of siRNAs specific for DNA enzyme synthesis and capsid 
proteins of cyprinid herpesvirus 3 virus can be a potential 
inhibitor of virus replication in carp fibroblasts (92). Along the 
same line, Gotesman et al. demonstrated that siRNAs can inhibit 
the thymidine kinase and DNA polymerase genes of cyprinid 
herpesvirus 3, causing decreased release of viral particles from 
transfected common carp brain cells (93). Viral infection in 
shrimp constitutes a great problem, and excellent reviews have 
discussed the use of RNAi in controlling various viral infections 
in shrimp [e.g., Ref. (94–96)].
Potential Use of RNAi to Create 
Genetically engineered virus-Resistant 
Animals
Genetic selection has been successful in mediating remark-
able progress in livestock improvement. Genetic engineering 
of livestock is commonly used to produce pharmaceuticals or 
to enhance production characteristics of animals but has also 
proven to be important in producing animals with infectious 
disease resistance. For example, cows have been genetically engi-
neered to be resistant against Staphylococcus aureus-induced 
mastitis (97), and laboratory investigations have been conducted 
with regard to creating α-herpesvirus-resistant livestock (98). 
Furthermore, there are efforts to create livestock resistant against 
gastroenteritis coronavirus infection, but published studies are 
limited to work with mice (99). Against IAV infection, two 
potent lentivirus-based shRNAs targeting the NP and PA genes 
of IAV were used to generate IAV-resistant mice (100). However, 
a successful challenge experiment has not been reported in this 
system. Subsequent studies based on inhibiting genes of other 
pathogens have been conducted (61). With improved RNAi 
techniques, it is conceivable that genetically engineered disease-
resistant animals, based on siRNA or shRNA technology, may 
someday become reality in veterinary infectious disease medi-
cine. Even prion diseases have been the target of transgenic-
animal technology featuring shRNAs. Golding and colleagues 
attempted the use of siRNA technology to generate prion-resist-
ant goat and cattle (101). First, they designed a lentivirus-based 
shRNA tagged with green fluorescent protein (GFP), which was 
directed against caprine prion protein precursor (PrPc) mRNA 
and then transfected this vector into an adult goat fibroblast cell 
line. These cells were then used for somatic nuclear transfer to 
produce transgenic goat embryos for subsequent in  vitro dif-
ferentiation in various stages of pre-implantation development. 
They confirmed the silencing capacity of shRNA in brain tissue 
of the growing fetus compared to an age-matched normal fetus. 
The authors observed an approximate 90% reduction in the 
expression of PrPc. However, clinical efficacy in reducing the risk 
of a neurodegenerative disease was not determined, and data 
regarding efficacy were not presented. This suggests that this 
technique had surpassed a major technical hurdle. Furthermore, 
two studies described the efficacy of RNAi to silence FMDV in 
transgenic bovine fetal epithelium cells (BFEC), although rigor-
ous negative controls were lacking, making it difficult to ascribe 
any effects to the transgenic manipulations. The first of these was 
conducted by Wang et al., who describe the construction of three 
recombinant lentiviral vectors containing shRNA against VP2 
(RNAi-VP2), VP3 (RNAi-VP3), or VP4 (RNAi-VP4) of FMDV 
and subsequent testing of their silencing power in both 293 and 
BHK-21 cells (102). The lenti-RNAi-VP4 vector was transfected 
into bovine fetal fibroblast cells. The stably transfected cells 
were transferred into enucleated oocytes, and the reconstructed 
embryos were then transferred to recipient cows. shRNA 
expressed in transgenic fetuses significantly degraded viral 
RNA after inoculation with FMDV at a titer of 100 TCID50 and 
inhibited viral replication. Thus, primary transgenic bovine fetus 
tongue epithelium cells became much more resistant to FMDV 
challenge. In the second report, a shRNA-expressing lentiviral 
vector targeting VP1 of FMDV resulted in strong suppression 
of VP1 protein expression in 293T cells and also significantly 
inhibited viral replication in BHK-21 cells (103). The construct 
was then transfected into bovine fetal fibroblast cells. Cloning 
these somatic cells resulted in 3-month-old transgenic fetuses. 
FMDV RNA synthesis and viral replication were significantly 
reduced in primary tongue epithelial cells from the transgenic 
fetuses, suggesting that RNAi technology can be potentially 
used to generate transgenic cattle resistant against FMDV. 
Taken together, the studies summarized above support the idea 
that transgenic cloning may prove to be a useful tool to deliver 
antiviral and anti-prion RNAi to the germ line of animals of 
veterinary importance, but substantial additional work remains 
to be done before this technology may demonstrate efficacy in 
veterinary practice.
ReMAiNiNG CHALLeNGeS
Despite the excitement about utilizing non-coding RNAs to 
combat animal viral diseases, considerable challenges still need 
to be overcome before they can be used clinically. Animal breed-
ers tend to rear their flocks in large groups under intensive or 
semi-intensive husbandry or on large farms. It would be wasteful 
in terms of money, time, and labor to deliver these expensive 
molecules on an individual basis. In this case, most veterinarians 
prefer to use antiviral therapies in a common source bio-vehicle, 
for instance, food, water, or air, to ensure quick accessibility. We 
think that using individual miRNA-based therapies will be more 
practical in special cases, such as the following: race horses, the 
very expensive parent flocks of chickens and turkeys that are 
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intended for production of specific pathogen-free (SPF) eggs, 
purebred domestic animals kept as stock for distributing semen 
for artificial insemination, and cross breeding and improving cer-
tain animal traits for meat, milk, or fat production. Controlling 
contagious viral diseases, for instance, FMDV and IAV, neces-
sitates a rapid intervention strategy to prevent virus spread from 
one farm to another and from animals to human. In this regard, 
RNAi that produces the inhibitory effect within 1 or 2 days in cell 
lines is considered to be insufficient, and a more rapidly operating 
approach is needed. Another technical challenge is that the exces-
sive levels of the introduced miRNAs can saturate the internal 
host processing machine for other host small RNAs giving rise 
to toxicity, pathology, and mortality to the animal under therapy 
(104). Therefore, the dose of the introduced RNAi-based therapy 
should be well controlled. The delivery of the RNAi molecule 
is a key roadblock in this whole process. This is because RNAi 
molecules are negatively charged and do not penetrate the cell 
membrane effectively, a step that is necessary for subsequent 
silencing of mRNAs in the cytoplasm (105). Additionally, they 
may be quickly excreted, of low stability, non-tissue specific, and 
may have an inefficient intracellular release (106). Although the 
delivery of the silencing molecule may be mediated via vectors, 
suboptimal vector selection might reduce the silencing effect. 
Many delivery systems, such as nanoparticles, cationic lipids, cal-
cium phosphate, antibodies, cholesterol, and viral vectors, have 
been tested (107). From another perspective, the use of a single 
RNAi silencing molecule with a low percent match with the target 
mRNA would lead to a poor target reduction. Possible solutions 
include either applying only one siRNA which is 100% identical 
to the sequences of interest or applying more than one siRNA 
sequence targeting different conserved regions of the target gene. 
In the case of IAV, spontaneous mutations were estimated to 
occur at a rate of approximately 1.5 ×  10−5 per nucleotide per 
infection cycle (50), suggesting that target sequence mismatches 
will arise inevitably. Another challenge is to develop a universal 
RNAi molecule against the same sequence in multiple influenza 
strains. Some viruses may evolve mechanisms to circumvent the 
targeting RNAi molecule, either by expressing virus-encoded 
suppressors or by mutation (108). In order to avoid this, scientists 
have tried to design RNAi molecules that simultaneously target 
several sequences within a viral gene (109). In practice, in the fish 
aquaculture system, RNAi-based therapy have demonstrated some 
limitations. As a rearing system in some fish farms, the rearing 
cages are kept floating in the sea or river water, the so-called open 
sea or river cage aquaculture. Under such system, introducing 
RNAi molecules into fish feed will allow settlement of the uneaten 
food, containing the therapy, to the bottom of the water body. 
This would be ineffective and would also make the feed available 
to non-target organisms (110). Thus, an alternative improved 
approach would be to use RNAi in land-based ponds or tanks, 
owing to their direct accessibility to fish and the easy disposal of 
waste materials. The commercial field application of injectable 
therapy is neither practical nor realistic, especially with shrimp, 
which are reared in an intensive system. Despite its relatively 
high expense, soaking the shrimp in a solution containing the 
RNAi silencing molecule is a more practical way to ensure that an 
effective suppression of the gene is achieved (111). Unfortunately, 
there are no shrimp cell lines available for the research com-
munity, delaying a better understanding of the RNAi application 
in shrimp farms. Effective design of the RNAi molecule is also 
of special concern. Although various computational tools have 
been developed to systematically evaluate the targets for miRNAs 
and or siRNA (112–114), non-specific off-target effects need to 
be anticipated. The many parameters that influence specificity of 
miRNAs/siRNAs include the selected target region, size, the start-
ing nucleotide, GC content, the thermodynamic properties of the 
introduced molecule, and the presence of internal repeats. Apart 
from an effective design, the use of accurate positive and negative 
controls is necessary to ensure the validity of RNAi data (115).
FUTURe DiReCTiONS
From the evidence gathered thus far, we have every reason to 
be optimistic about the future use of sncRNAs in the diagnosis, 
monitoring, and treatment of animal viral diseases. Zoonotic 
viruses continue to pose a public health threat to humans. There 
are miRNAs that are associated with zoonotic viral diseases that 
were found to be conserved among the human and animal reser-
voirs and exhibit similar tissue tropism. It is import to investigate 
both the contribution of these miRNAs to the zoonotic nature of 
diseases and their potential roles as biomarkers or therapeutic 
tools for humans and animals. This is even more important for 
viral diseases affecting poultry populations that are reared under 
both intensive and semi-intensive systems, where the pathogens 
can be transmitted in a short time to populate the environment 
and infect susceptible hosts. Regarding the use of RNAi in com-
bating viruses, the search for a target sequence conserved across 
strains is of highest priority in studies targeting animal viruses, 
in particular, those featuring rapid genomic changes, such as IAV 
and other RNA viruses. However, using a pool of various siRNAs 
or a cocktail of siRNAs specific for virus and host genes might 
reduce escape of mutant viruses. In addition, it would be valuable 
to develop more rapidly acting RNAi technology to inhibit spread 
of highly contagious infections, such as FMD. Prospectively, 
incorporating the RNAi molecule into animal feed or the water 
supply might be a practical choice for the treatment of animals 
reared in large numbers, such as fish or poultry. Using this strategy, 
successful experiments have been recorded in shrimp infected 
with white spot syndrome virus (WSSV) (116). In spite of the 
extensive efforts toward formulating a suitable vehicle, one that 
delivers the smallest RNAi quantity in a non-toxic way remains 
to be discovered. In this respect, the use of a natural exosome or 
a natural or synthetic high-density lipoprotein (HDLP) is a novel 
and promising approach. These are just a few areas of research 
that are likely to engage veterinary scientists and virologists for 
years ahead. These and other improvements should further facili-
tate the use of miRNA and siRNA to prevent and control animal 
viruses at veterinary clinical sites and in the field.
CONCLUSiON
Small non-coding RNAs have been known as crucial regula-
tors of gene expression, and they have great potential for 
applications in the diagnosis, prevention, and treatment of 
FiGURe 2 | Diagrammatic illustration of potential uses of non-coding RNAs to combat animal viruses. miRNAs can be used as biomarkers for pinpointing 
animal viral diseases. They can act as potential therapies and to create genetically virus-resistant animal breeds. Abbreviations: RT-qPCR, reverse transcriptase 
quantitative real-time PCR; RNAi, RNA interference; siRNA, small interfering RNA; GO, gene ontology. Adapted from UGA Veterinary Diagnostic Laboratories, 
Werner et al. (117), and Livingston et al. (118).
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viral infectious diseases of veterinary importance. Research 
efforts are continuing to translate RNAi technology with its 
two arms, miRNAs and siRNA, to clinical applications in 
veterinary medicine (Figure 2). In this respect, the deregula-
tion of miRNAs upon infection, their stability, and tissue 
specificity have made their study as biomarkers a fruitful area 
of research. siRNA molecules together with miRNA mimics or 
agonists can be delivered to the infected animal as a treatment 
option. Although there are currently no genetically engineered 
virus-resistant animals, the likelihood of exploiting RNAi 
technology, including miRNAs, is growing and is expected to 
help attain this aim. Bringing these molecules to the market 
will remain to be challenging and many barriers still need to be 
overcome. In fact, in vitro models would enable more detailed 
studies on the clinical relevance of these molecules. However, 
experimental animal models and infections of natural hosts 
in laboratory investigations will afford more realistic insights 
into the best ways to utilize sncRNAs to improve animal health. 
Importantly, developing animal-specific databases that contain 
experimentally validated small RNA molecules and related 
functional analysis will facilitate using these data for future 
research. The continual emergence of zoonotic viruses warrants 
effective collaborations between physicians and veterinarians 
in this issue. The available evidence suggests that the clinical 
use of sncRNAs in combating animal viruses may be possible 
in the not too distant future.
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